FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022265683> ?p ?o ?g. }

• W2022265683 endingPage "1624" @default.
• W2022265683 startingPage "1617" @default.
• W2022265683 abstract "Finding an effective treatment strategy for rheumatoid arthritis (RA) patients who have not benefited from previous tumor necrosis factor-α antagonist treatment is important for minimizing RA disease activity and improving patient outcomes. The aim of this study was to compare the safety and effectiveness of etanercept in patients with and without infliximab (IFX) treatment experience. Patients (n = 7,099) from a large postmarketing observational study of etanercept use in Japan were divided into 2 cohorts based on previous IFX use (pre-IFX and non-IFX). Baseline characteristics were assessed in each cohort. Adverse events (AEs) and European League Against Rheumatism (EULAR) responses were monitored every 4 weeks for 24 weeks. At baseline, pre-IFX patients were younger and had fewer comorbidities and a shorter RA duration than non-IFX patients. During the study, pre-IFX patients received concomitant methotrexate more often than non-IFX patients. The incidence of AEs and serious AEs were significantly lower in pre-IFX patients, as was the percentage of patients who discontinued treatment. Both cohorts had significant improvement (P < 0.001) in EULAR responses at the end of the treatment period. This study demonstrated that etanercept was effective and well tolerated in active RA patients with and without prior IFX treatment." @default.
• W2022265683 created "2016-06-24" @default.
• W2022265683 creator A5000387001 @default.
• W2022265683 creator A5010908061 @default.
• W2022265683 creator A5015953107 @default.
• W2022265683 creator A5020721553 @default.
• W2022265683 creator A5041927706 @default.
• W2022265683 creator A5053803963 @default.
• W2022265683 creator A5060016936 @default.
• W2022265683 creator A5063192431 @default.
• W2022265683 creator A5075389231 @default.
• W2022265683 creator A5081879009 @default.
• W2022265683 creator A5083314956 @default.
• W2022265683 creator A5089659933 @default.
• W2022265683 date "2011-02-18" @default.
• W2022265683 modified "2023-10-18" @default.
• W2022265683 title "Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study" @default.
• W2022265683 cites W1985763670 @default.
• W2022265683 cites W1991500317 @default.
• W2022265683 cites W1996389186 @default.
• W2022265683 cites W1996472975 @default.
• W2022265683 cites W1997106678 @default.
• W2022265683 cites W2018600081 @default.
• W2022265683 cites W2024644107 @default.
• W2022265683 cites W2062894373 @default.
• W2022265683 cites W2079172449 @default.
• W2022265683 cites W2106453726 @default.
• W2022265683 cites W2111153776 @default.
• W2022265683 cites W2112966993 @default.
• W2022265683 cites W2116843833 @default.
• W2022265683 cites W2122000071 @default.
• W2022265683 cites W2122265491 @default.
• W2022265683 cites W2124243366 @default.
• W2022265683 cites W2124670599 @default.
• W2022265683 cites W2125935509 @default.
• W2022265683 cites W2140231842 @default.
• W2022265683 cites W2319957449 @default.
• W2022265683 cites W2328587823 @default.
• W2022265683 cites W334564628 @default.
• W2022265683 cites W4361867558 @default.
• W2022265683 doi "https://doi.org/10.1007/s00296-011-1807-0" @default.
• W2022265683 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3364424" @default.
• W2022265683 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21331576" @default.
• W2022265683 hasPublicationYear "2011" @default.
• W2022265683 type Work @default.
• W2022265683 sameAs 2022265683 @default.
• W2022265683 citedByCount "10" @default.
• W2022265683 countsByYear W20222656832014 @default.
• W2022265683 countsByYear W20222656832015 @default.
• W2022265683 countsByYear W20222656832017 @default.
• W2022265683 countsByYear W20222656832018 @default.
• W2022265683 crossrefType "journal-article" @default.
• W2022265683 hasAuthorship W2022265683A5000387001 @default.
• W2022265683 hasAuthorship W2022265683A5010908061 @default.
• W2022265683 hasAuthorship W2022265683A5015953107 @default.
• W2022265683 hasAuthorship W2022265683A5020721553 @default.
• W2022265683 hasAuthorship W2022265683A5041927706 @default.
• W2022265683 hasAuthorship W2022265683A5053803963 @default.
• W2022265683 hasAuthorship W2022265683A5060016936 @default.
• W2022265683 hasAuthorship W2022265683A5063192431 @default.
• W2022265683 hasAuthorship W2022265683A5075389231 @default.
• W2022265683 hasAuthorship W2022265683A5081879009 @default.
• W2022265683 hasAuthorship W2022265683A5083314956 @default.
• W2022265683 hasAuthorship W2022265683A5089659933 @default.
• W2022265683 hasBestOaLocation W20222656831 @default.
• W2022265683 hasConcept C120665830 @default.
• W2022265683 hasConcept C121332964 @default.
• W2022265683 hasConcept C126322002 @default.
• W2022265683 hasConcept C197636746 @default.
• W2022265683 hasConcept C197934379 @default.
• W2022265683 hasConcept C198451711 @default.
• W2022265683 hasConcept C2777138892 @default.
• W2022265683 hasConcept C2777226972 @default.
• W2022265683 hasConcept C2777489490 @default.
• W2022265683 hasConcept C2777575956 @default.
• W2022265683 hasConcept C2779134260 @default.
• W2022265683 hasConcept C2779384505 @default.
• W2022265683 hasConcept C2781059491 @default.
• W2022265683 hasConcept C61511704 @default.
• W2022265683 hasConcept C71924100 @default.
• W2022265683 hasConcept C72563966 @default.
• W2022265683 hasConceptScore W2022265683C120665830 @default.
• W2022265683 hasConceptScore W2022265683C121332964 @default.
• W2022265683 hasConceptScore W2022265683C126322002 @default.
• W2022265683 hasConceptScore W2022265683C197636746 @default.
• W2022265683 hasConceptScore W2022265683C197934379 @default.
• W2022265683 hasConceptScore W2022265683C198451711 @default.
• W2022265683 hasConceptScore W2022265683C2777138892 @default.
• W2022265683 hasConceptScore W2022265683C2777226972 @default.
• W2022265683 hasConceptScore W2022265683C2777489490 @default.
• W2022265683 hasConceptScore W2022265683C2777575956 @default.
• W2022265683 hasConceptScore W2022265683C2779134260 @default.
• W2022265683 hasConceptScore W2022265683C2779384505 @default.
• W2022265683 hasConceptScore W2022265683C2781059491 @default.
• W2022265683 hasConceptScore W2022265683C61511704 @default.
• W2022265683 hasConceptScore W2022265683C71924100 @default.
• W2022265683 hasConceptScore W2022265683C72563966 @default.
• W2022265683 hasIssue "6" @default.

• next